Pharma & Bio
Technology
[Bio Spotlight] i-SENS, Inc. Rises 9% on ‘Earnings Surprise’… Peptron, Inc. and Cellid Co., Ltd. Also Soar
On the 27th, in the domestic pharmaceutical and biotech stock market, i-SENS, Inc.(099190)saw its stock price surge after reporting second-quarter earnings that significantly exceeded market expectati…
Technology
Kolon TissueGene Avoids Fourth Consecutive Limit-Down; Peptron Jumps in After-Hours Trading [K-Bio Pulse]
South Korea’s biotech sector showed sharp divergence on July 24. Kolon TissueGene narrowly avoided a fourth consecutive limit-down close, while Peptron surged in after-hours trading on expectations fo…
Technology
Kolon TissueGene, Inc. Falls for 4 Consecutive Days… Why Did Peptron, Inc. Surge in After-Hours Trading? [Bio Spotlight]
On the 24th, in the biotech sector, Kolon TissueGene, Inc. narrowly avoided hitting the daily price limit down for the fourth consecutive trading day. Peptron, Inc. saw its stock price show strength i…
Lifestyle
Huino Expected to Surpass 15 Billion Won in Annual Sales as It Steps Up Sales of Yuhan Corporation’s ‘Memo Q’
Yuhan(000100), a strategic investor (SI) and distribution partner of Huino, a leading digital healthcare company, has significantly expanded its purchase volume of new in-hospital monitoring solutions…
Technology
Celltrion Enters Era of 60% Revenue from New Products... Full-Scale Efforts to Diversify Revenue and Boost Profitability Underway
Celltrion(068270)Analysts note that as the company reduces its reliance on “Remsima” and expands its product portfolio with high-margin products, revenue diversification and profitability growth are g…
Technology
The COVID-19 Boom Is Over… What Happened to the Korean Diagnostic Kits That Survived in the U.S.?
The U.S. will end the Emergency Use Authorization (EUA) system for diagnostic kits—which was temporarily permitted during the COVID-19 pandemic—at the end of this year. Going forward, the U.S. COVID-1…
Manufacturing
"Driven by PDRN, a New Growth Engine Derived from Ultra-Nano Probiotics, the Company Aims to Double Sales This Year and Return to Profit Next Year" [In-Depth Look at AccuGen ③]
AccuGen is accelerating its expansion into new bio-material businesses, including cosmetic and health functional food ingredients based on polydeoxyribonucleotide (PDRN) derived from lactic acid bacte…
Manufacturing
"Strengths in One-Stop Comprehensive Microbial Services, from AI Analysis to the Development, Production, and Delivery of Consumables" [In-Depth Look at AccuGen ②]
AccuGen is the only company in Korea to offer a one-stop comprehensive service that encompasses microbial analysis as well as the development, production, and delivery of consumables. AccuGen also hol…
Manufacturing
"Leaping from Genetic Testing and Medical Device Consumables to a Natural Microbial Materials Company" [In-Depth Look at AccuGen ①]
"We will transform AccuGen from a company specializing in genetic sample collection tubes and kits, as well as next-generation sequencing (NGS) microbiome testing, into a leading provider of natural m…
Business·Industry
A Look at Precedents in K-Bio That Claimed 'Half a Success'… Will Kolon TissueGene, Inc.’s 'TG-C' Be Different?
Jeon Seung-ho, co-CEO of Kolon TissueGene, Inc., held a press conference in Gangseo-gu, Seoul, on the 21st to announce the results of the U.S. Phase 3 clinical trial for “TG-C,” a cell-gene therapy fo…